Apollo SRI, LLC, with offices in Houston, Texas and Burlington, Vermont, provides the research industry with specialty mesoporous silica products. Apollo BioSciences is commercializing its Pharmefex⢠technology developed at the University of Vermont into a potent drug delivery platform for cancer treatment. The first two products in the Apollo pipeline are Pharmefex⢠+ DOX (doxorubicin) for treatment of mesothelioma and Pharmefex⢠+ DTIC (dacarbazine) for treatment of melanoma. In addition, Apollo is exploring the potential for Pharmefex⢠in the delivery of siRNA and shRNA to cells. Pharmefex⢠is a monodispersed, spherical silica-based particle with a disordered pore structure with a surface that can be modified to facilitate selective uptake, making it attractive for drug delivery. Preliminary research indicates Pharmefex⢠increased the effectiveness of select chemotherapy drugs by greater than 700 percent in the apoptosis of mesothel
